Licensing application for bazedoxifene/conjugated oestrogens for treatment of oestrogen deficiency symptoms and osteoporosis accepted for review in EU (NeLM News Service, 20 July 2012)

23 Jul 2012

The European Medicines Agency has accepted for review a marketing application for bazedoxifene (a selective oestrogen receptor modulator) in combination with conjugated oestrogens for use in postmenopausal women with a uterus for the treatment of oestrogen deficiency symptoms and treatment of osteoporosis in those at risk of fracture. A decision is expected in 2013.

Full article

Licensing application for bazedoxifene/conjugated oestrogens for treatment of oestrogen deficiency symptoms and osteoporosis accepted for review in EU (NeLM News Service, 20 July 2012)

Share this story

Top stories

Most read